Status:
COMPLETED
Magnesium and Ketamine in Postoperative Analgesia
Lead Sponsor:
National Cancer Institute, Egypt
Conditions:
Postoperative Analgesia
Eligibility:
FEMALE
18-65 years
Phase:
PHASE4
Brief Summary
90 female patients scheduled for cancer breast surgeries will be assigned to 2 groups, each of 45. Group (K) will receive a bolus of 0.5 mg/kg ketamine with induction of anaesthesia, followed by ketam...
Detailed Description
90 female patients aged between 18 and 65 years, scheduled for cancer breast surgeries will be assigned to 2 groups, each of 45. Group (K) will receive a bolus of 0.5 mg/kg ketamine with induction of ...
Eligibility Criteria
Inclusion
- Patients with class II physical status (American Society of Anaesthesiologists) ,
- Age between 18-65 years,
- Scheduled for breast cancer surgery (e.g. modified radical mastectomy and conservative mastectomy)
Exclusion
- Patient refusal,
- Cardiac dysfunction (ejection fraction \<45%),
- Diabetic patients
- Patients with uncontrolled hypertension
- Patients have any degree of heart block
- Patients have renal impairment (creatinine \> 2 mg/dl),
- Patients have hepatic dysfunction (transaminases \> 2 times normal),
- Patients with preexisting neurological or psychiatric disease,
- Patients who are allergic to one of the study drugs,
- Patients with communication difficulties,
- Inability to use the patient controlled analgesia (PCA) device,
- Female patients who are pregnant
- Patients who use preoperative calcium channel blockers or narcotic drugs.
Key Trial Info
Start Date :
November 1 2019
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2020
Estimated Enrollment :
90 Patients enrolled
Trial Details
Trial ID
NCT04111848
Start Date
November 1 2019
End Date
December 1 2020
Last Update
March 2 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
National Cancer Institute
Cairo, Egypt